| Original language | English (US) |
|---|---|
| Pages (from-to) | 774A |
| Journal | Clinical Research |
| Volume | 29 |
| Issue number | 4 |
| State | Published - 1981 |
Bibliographical note
Funding Information:The peptides were obtained commercially: bombesin (0.1-10.0 /xg ICV: Sigma Chemical Company, St. Louis, MO); neurotensin (10/xg ICV: Vega Chemicals, Reno, NV); thyrotropin releasing hormone (TRH 0.1-10.0 /xg ICV: Boehringer-Mannheim, Indianapolis, IN); somatostatin (10 /xg ICV: Beckman, Palo Alto, CA); pyro-glutamyl histidyl proline (acid TRH 1.0-10.0 tzg ICV: Vega Biochemicals, Tuscon, AZ); substance P (10/zg ICV: Vega Biochemicals, Tucson, AZ); calcitonin (0.02-2.0 units ICV: Armour Pharmaceutical Company, Phoenix, AZ), histidyl-proline di-latopiperazine (cHis-Pro 10 /zg ICV: Vega Biochemicals Company, Tucson, AZ). All peptides were administered ICV in five microliters of physiological saline. Control animals ~This work was supported by the Veterans Administration Research Service. 2Requests for reprints should be addressed to John E. Morley, M.B., B. Ch., Minneapolis VA Medical Center, Minneapolis, MN 55417.
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.